Published in Am J Gastroenterol on May 01, 2003
Diagnostic criteria for autoimmune chronic pancreatitis revisited. World J Gastroenterol (2006) 1.82
ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol (2015) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol (2008) 0.94
Approach to a patient with elevated serum alkaline phosphatase. Clin Liver Dis (2012) 0.88
Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract (2012) 0.85
Primary sclerosing cholangitis: outcome of patients undergoing restorative proctocolecetomy for ulcerative colitis. Int J Colorectal Dis (2009) 0.81
Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist. World J Hepatol (2015) 0.80
The predictors of the presence of varices in patients with primary sclerosing cholangitis. Hepatology (2010) 0.80
Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. J Interferon Cytokine Res (2013) 0.80
T helper 17 cells in autoimmune liver diseases. Clin Dev Immunol (2013) 0.79
What is the current role of endoscopy in primary sclerosing cholangitis? World J Gastrointest Endosc (2015) 0.76
The evolution of natural history of primary sclerosing cholangitis. Curr Opin Gastroenterol (2016) 0.75
The Diagnostic Value of Endoscopic Balloon Catheter Usage for Detecting Early-Stage Primary Sclerosing Cholangitis in Endoscopic Retrograde Cholangiopancreatography: A Case Report. Case Rep Gastroenterol (2010) 0.75
Successful low-dose azathioprine for myasthenia gravis despite hepatopathy from primary sclerosing cholangitis: a case report. J Med Case Rep (2010) 0.75
A gentleman with anemia and cholestasis. Case Rep Med (2010) 0.75
Percutaneous liver biopsy: reflections and refinements. Can J Gastroenterol (2006) 0.75
Primary sclerosing cholangitis--approach to diagnosis. MedGenMed (2007) 0.75
A morphometric study of the hepatic arterioles in end-stage primary sclerosing cholangitis. Virchows Arch (2014) 0.75
[Liver biopsy at the intersection of clinical and pathological diagnosis]. Pathologe (2008) 0.75
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol (2005) 2.46
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology (2006) 2.25
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology (2006) 2.06
Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med (2011) 2.03
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (2008) 2.02
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
The natural history of small-duct primary sclerosing cholangitis. Gastroenterology (2008) 1.92
Primary biliary cirrhosis. Lancet (2003) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg (2011) 1.78
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology (2010) 1.60
Primary sclerosing cholangitis. Lancet (2013) 1.59
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.49
Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol (2003) 1.48
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2005) 1.48
Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2003) 1.47
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Research productivity of graduates from 3 physician-scientist training programs. Am J Med (2008) 1.44
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res (2010) 1.43
The value of observational research in liver diseases. Hepatology (2011) 1.43
Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol (2008) 1.41
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Recurrent idiopathic hepatitis: a new entity? J Clin Gastroenterol (2003) 1.38
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol (2010) 1.37
Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol (2002) 1.33
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int (2005) 1.27
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res (2011) 1.23
Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology (2002) 1.20
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Bone disease in patients with primary sclerosing cholangitis. Gastroenterology (2010) 1.15
The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int (2012) 1.15
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res (2011) 1.15
Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol (2002) 1.14
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13
Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. Hepatology (2011) 1.12
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.12
Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology (2005) 1.12
Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol (2005) 1.10
Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis (2008) 1.09
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology (2003) 1.07
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci (2014) 1.07
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology (2004) 1.06
The cytoplasmic dot staining pattern is detected in a subgroup of patients with primary biliary cirrhosis. J Rheumatol (2005) 1.05
Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci (2010) 1.05
Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis (2012) 1.05
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology (2005) 1.05